<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR941028-2-00170</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=85 g=1 f=1 --> Table 3. Characteristics of an Effective Tuberculosis (TB) Infection-Control Program* <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=1 f=1 --> I. Assignment of responsibility <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <FOOTNOTE> <!-- PJG ITAG l=28 g=1 f=1 --> *A program such as this is appropriate for health-care facilities in which there is a high risk for transmission of  <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=3 --> Mycobacterium tuberculosis. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> </FOOTNOTE>  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=3 --> A. Assign responsibility for the TB infection-control program to qualified person(s). <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> B. Ensure that persons with expertise in infection control, occupational health, and engineering are identified and included. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=1 f=3 --> II. Risk assessment, TB infection-control plan, and periodic reassessment <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=3 --> A. Initial risk assessments <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 1. Obtain information concerning TB in the community. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 2. Evaluate data concerning TB patients in the facility. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 3. Evaluate data concerning purified protein derivative (PPD)-tuberculin skin-test conversions among health-care workers (HCWs) in the facility. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 4. Rule out evidence of person-to-person transmission. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> B. Written TB infection-control program <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 1. Select initial risk protocol(s). <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 2. Develop written TB infection-control protocols. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> C. Repeat risk assessment at appropriate intervals. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 1. Review current community and facility surveillance data and PPD-tuberculin skin-test results. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 2. Review records of TB patients. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 3. Observe HCW infection-control practices. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 4. Evaluate maintenance of engineering controls. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=1 f=3 --> III. Identification, evaluation, and treatment of patients who have TB <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=3 --> A. Screen patients for signs and symptoms of active TB: <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 1. On initial encounter in emergency department or ambulatory-care setting. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 2. Before or at the time of admission. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> B. Perform radiologic and bacteriologic evaluation of patients who have signs and symptoms suggestive of TB. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> C. Promptly initiate treatment. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=1 f=3 --> IV. Managing outpatients who have possible infectious TB <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=3 --> A. Promptly initiate TB precautions. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> B. Place patients in separate waiting areas or TB isolation rooms. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> C. Give patients a surgical mask, a box of tissues, and instructions regarding the use of these items. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=1 f=3 --> V. Managing inpatients who have possible infectious TB <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=3 --> A. Promptly isolate patients who have suspected or known infectious TB. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> B. Monitor the response to treatment. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> C. Follow appropriate criteria for discontinuing isolation. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=1 f=3 --> VI. Engineering recommendations <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=3 --> A. Design local exhaust and general ventilation in collaboration with persons who have expertise in ventilation engineering. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> B. Use a single-pass air system or air recirculation after high-efficiency particulate air (HEPA) filtration in areas where infectious TB patients receive care. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> C. Use additional measures, if needed, in areas where TB patients may receive care. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> D. Design TB isolation rooms in health-care facilities to achieve "6 air changes per hour (ACH) for existing facilities and "12 ACH for new or renovated facilities. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> E. Regularly monitor and maintain engineering controls. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> F. TB isolation rooms that are being used should be monitored daily to ensure they maintain negative pressure relative to the hallway and all surrounding areas. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> G. Exhaust TB isolation room air to outside or, if absolutely unavoidable, recirculate after HEPA filtration. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=1 f=3 --> VII. Respiratory protection <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=3 --> A. Respiratory protective devices should meet recommended performance criteria. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> B. Respiratory protection should be used by persons entering rooms in which patients with known or suspected infectious TB are being isolated, by HCWs when performing cough-inducing or aerosol-generating procedures on such patients, and by persons in other settings where administrative and engineering controls are not likely to protect them from inhaling infectious airborne droplet nuclei. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> C. A respiratory protection program is required at all facilities in which respiratory protection is used. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=1 f=3 --> VIII. Cough-inducing procedures <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=3 --> A. Do not perform such procedures on TB patients unless absolutely necessary. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> B. Perform such procedures in areas that have local exhaust ventilation devices (e.g., booths or special enclosures) or, if this is not feasible, in a room that meets the ventilation requirements for TB isolation. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> C. After completion of procedures, TB patients should remain in the booth or special enclosure until their coughing subsidies. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=1 f=3 --> IX. HCW TB training and education <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=3 --> A. All HCWs should receive periodic TB education appropriate for their work responsibilities and duties. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> B. Training should include the epidemiology of TB in the facility. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> C. TB education should emphasize concepts of the pathogenesis of and occupational risk for TB. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> D. Training should describe work practices that reduce the likelihood of transmitting M. tuberculosis. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=1 f=3 --> X. HCW counseling and screening <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=3 --> A. Counsel all HCWs regarding TB and TB infection. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> B. Counsel all HCWs about the increased risk to immunocompromised persons for developing active TB. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> C. Perform PPD skin tests on HCWs at the beginning of their employment, and repeat PPD tests at periodic intervals. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> D. Evaluate symptomatic HCWs for active TB. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=1 f=3 --> XI. Evaluate HCW PPD test conversions and possible nosocomial transmission of M. tuberculosis. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> XII. Coordinate efforts with public health department(s) <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            